Symbols / DRUG Stock $88.82 -0.10% Bright Minds Biosciences Inc.
DRUG (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Ratings
Current target
$89.50
Low
$144.74
High
$192.97
Mean
$161.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-13 | init | Jefferies | — → Buy | $145 |
| 2026-03-30 | reit | BTIG | Buy → Buy | $147 |
| 2026-03-04 | main | HC Wainwright & Co. | Buy → Buy | $145 |
| 2026-02-17 | main | BTIG | Buy → Buy | $147 |
| 2026-01-07 | main | BTIG | Buy → Buy | $147 |
| 2026-01-06 | main | BTIG | Buy → Buy | $147 |
| 2026-01-02 | main | Chardan Capital | Buy → Buy | $80 |
| 2025-12-30 | reit | HC Wainwright & Co. | Buy → Buy | $115 |
| 2025-09-15 | reit | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-09-08 | init | BTIG | — → Buy | $72 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-05-21 | main | Chardan Capital | Buy → Buy | $80 |
| 2025-05-13 | init | TD Cowen | — → Buy | — |
| 2025-05-07 | init | Chardan Capital | — → Buy | $80 |
| 2025-02-19 | reit | HC Wainwright & Co. | Buy → Buy | $85 |
| 2025-01-23 | init | Piper Sandler | — → Overweight | $93 |
| 2025-01-10 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-01-10 | init | HC Wainwright & Co. | — → Buy | $85 |
| 2024-11-25 | init | Baird | — → Outperform | $75 |
- Entrada’s stock drops as DMD drug’s efficacy falls short - Clinical Trials Arena Fri, 08 May 2026 10
- Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool Fri, 08 May 2026 02
- No approved hantavirus treatment; Traws plans drug push - Stock Titan Fri, 08 May 2026 11
- Recon: FDA to reconsider Atara, Pierre Fabre drug after surprise rejection; Amazon to stock Ozempic at US kiosks - RAPS.org hu, 07 May 2026 19
- This drug stock nears a buy point, with profit set to explode - MSN hu, 07 May 2026 07
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up - Yahoo Finance hu, 07 May 2026 15
- Eli Lilly stock swings after FDA liver failure report for GLP-1 drug - thestreet.com Wed, 06 May 2026 15
- Bright Minds Biosciences (DRUG) to Release Earnings on Friday - MarketBeat Fri, 08 May 2026 05
- How This Biotech Scored 'A Clear Win' Where Bristol Myers Failed - Investor's Business Daily ue, 05 May 2026 20
- Trading Systems Reacting to (DRUG) Volatility - Stock Traders Daily hu, 07 May 2026 22
- Company agrees to stop selling GLP-1 drugs to US customers - Good Morning America Wed, 06 May 2026 19
- Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy? - The Motley Fool hu, 07 May 2026 17
- This Drug Stock Has Crushed the S&P 500 Over the Last Decade - Yahoo Finance Sat, 18 Apr 2026 07
- Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - Yahoo Finance ue, 17 Mar 2026 07
- This Drug Stock Has Crushed the S&P 500 Over the Last Decade - The Motley Fool Sat, 18 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
13.94
+393.76%
|
2.82
-61.78%
|
7.39
-50.68%
|
14.98
|
| Research And Development |
|
11.08
+839.36%
|
1.18
-76.40%
|
5.00
-58.95%
|
12.18
|
| Selling General And Administration |
|
2.57
+77.47%
|
1.45
-34.29%
|
2.20
-13.77%
|
2.55
|
| Selling And Marketing Expense |
|
0.43
+932.83%
|
0.04
-65.16%
|
0.12
-78.36%
|
0.55
|
| General And Administrative Expense |
|
2.14
+52.12%
|
1.40
-32.51%
|
2.08
+4.06%
|
2.00
|
| Salaries And Wages |
|
0.50
+0.71%
|
0.49
-57.30%
|
1.16
+1063.06%
|
0.10
|
| Other Gand A |
|
1.64
+80.02%
|
0.91
-1.48%
|
0.92
-51.37%
|
1.90
|
| Other Operating Expenses |
|
0.29
+45.88%
|
0.20
+5.64%
|
0.19
-23.21%
|
0.24
|
| Total Expenses |
|
13.94
+393.76%
|
2.82
-61.78%
|
7.39
-50.68%
|
14.98
|
| Operating Income |
|
-13.94
-393.76%
|
-2.82
+61.78%
|
-7.39
+50.68%
|
-14.98
|
| EBITDA |
|
-13.86
-404.13%
|
-2.75
+62.41%
|
-7.31
+51.14%
|
-14.97
|
| Normalized EBITDA |
|
-14.05
-412.74%
|
-2.74
+62.61%
|
-7.33
+51.08%
|
-14.98
|
| Reconciled Depreciation |
|
0.08
+4.79%
|
0.07
+1.25%
|
0.07
+1100.10%
|
0.01
|
| EBIT |
|
-13.94
-393.76%
|
-2.82
+61.78%
|
-7.39
+50.68%
|
-14.98
|
| Total Unusual Items |
|
0.19
+2127.15%
|
-0.01
-165.63%
|
0.01
+39.78%
|
0.01
|
| Total Unusual Items Excluding Goodwill |
|
0.19
+2127.15%
|
-0.01
-165.63%
|
0.01
+39.78%
|
0.01
|
| Special Income Charges |
|
—
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Impairment Of Capital Assets |
|
—
|
0.00
|
0.00
-100.00%
|
0.00
|
| Net Income |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Pretax Income |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Net Non Operating Interest Income Expense |
|
1.52
+4942.54%
|
0.03
|
0.00
|
0.00
|
| Net Interest Income |
|
1.52
+4942.54%
|
0.03
|
0.00
|
0.00
|
| Interest Income Non Operating |
|
1.52
+4942.54%
|
0.03
|
0.00
|
0.00
|
| Interest Income |
|
1.52
+4942.54%
|
0.03
|
0.00
|
0.00
|
| Other Income Expense |
|
0.19
+2127.15%
|
-0.01
-165.63%
|
0.01
+39.78%
|
0.01
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
-0.24
|
| Gain On Sale Of Security |
|
0.19
+2127.15%
|
-0.01
-165.63%
|
0.01
+16.77%
|
0.01
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Net Income From Continuing Operation Net Minority Interest |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Net Income From Continuing And Discontinued Operation |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Net Income Continuous Operations |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Normalized Income |
|
-12.42
-344.67%
|
-2.79
+62.19%
|
-7.39
+50.68%
|
-14.98
|
| Net Income Common Stockholders |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Diluted EPS |
|
-1.78
-173.85%
|
-0.65
+67.17%
|
-1.98
+67.33%
|
-6.06
|
| Basic EPS |
|
-1.78
-173.85%
|
-0.65
+67.17%
|
-1.98
+67.33%
|
-6.06
|
| Basic Average Shares |
|
6.88
+59.58%
|
4.31
+15.87%
|
3.72
+50.57%
|
2.47
|
| Diluted Average Shares |
|
6.88
+59.58%
|
4.31
+15.87%
|
3.72
+50.57%
|
2.47
|
| Diluted NI Availto Com Stockholders |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Total Assets |
|
84.42
+1282.92%
|
6.10
-11.26%
|
6.88
-43.09%
|
12.09
|
| Current Assets |
|
84.31
+1308.22%
|
5.99
-12.12%
|
6.81
-42.98%
|
11.95
|
| Cash Cash Equivalents And Short Term Investments |
|
82.91
+1349.43%
|
5.72
-15.23%
|
6.75
-41.97%
|
11.63
|
| Cash And Cash Equivalents |
|
82.91
+1349.43%
|
5.72
-15.23%
|
6.75
-41.97%
|
11.63
|
| Cash Equivalents |
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
|
| Cash Financial |
|
82.82
+1370.09%
|
5.63
-15.43%
|
6.66
-42.28%
|
11.54
|
| Receivables |
|
0.41
+722.46%
|
0.05
+35.81%
|
0.04
-76.26%
|
0.16
|
| Other Receivables |
|
—
|
—
|
—
|
0.04
|
| Taxes Receivable |
|
0.21
+317.96%
|
0.05
+35.81%
|
0.04
-67.71%
|
0.11
|
| Accrued Interest Receivable |
|
0.20
|
0.00
|
—
|
—
|
| Prepaid Assets |
|
0.99
+356.04%
|
0.22
+682.28%
|
0.03
-83.16%
|
0.16
|
| Total Non Current Assets |
|
0.11
-4.84%
|
0.12
+77.16%
|
0.07
-52.17%
|
0.14
|
| Net PPE |
|
0.11
-4.84%
|
0.12
+77.16%
|
0.07
-52.17%
|
0.14
|
| Gross PPE |
|
0.11
-4.84%
|
0.12
+77.16%
|
0.07
-52.17%
|
0.14
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Other Properties |
|
—
|
—
|
—
|
0.14
|
| Leases |
|
0.11
-4.84%
|
0.12
+77.16%
|
0.07
-52.17%
|
0.14
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
—
|
0.00
|
| Total Liabilities Net Minority Interest |
|
2.38
+318.23%
|
0.57
+102.33%
|
0.28
-81.82%
|
1.54
|
| Current Liabilities |
|
2.34
+341.73%
|
0.53
+88.24%
|
0.28
-80.93%
|
1.47
|
| Payables And Accrued Expenses |
|
2.25
+400.97%
|
0.45
+116.73%
|
0.21
-85.24%
|
1.40
|
| Payables |
|
1.71
+319.65%
|
0.41
+123.55%
|
0.18
-85.37%
|
1.25
|
| Accounts Payable |
|
1.71
+319.65%
|
0.41
+123.55%
|
0.18
-85.37%
|
1.25
|
| Current Accrued Expenses |
|
0.54
+1194.70%
|
0.04
+67.00%
|
0.03
-84.19%
|
0.16
|
| Current Debt And Capital Lease Obligation |
|
0.08
+6.48%
|
0.08
+7.93%
|
0.07
+8.27%
|
0.07
|
| Current Capital Lease Obligation |
|
0.08
+6.48%
|
0.08
+7.93%
|
0.07
+8.27%
|
0.07
|
| Total Non Current Liabilities Net Minority Interest |
|
0.04
+4.23%
|
0.04
|
0.00
-100.00%
|
0.07
|
| Long Term Debt And Capital Lease Obligation |
|
0.04
+4.23%
|
0.04
|
0.00
-100.00%
|
0.07
|
| Long Term Capital Lease Obligation |
|
0.04
+4.23%
|
0.04
|
0.00
-100.00%
|
0.07
|
| Stockholders Equity |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Common Stock Equity |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Capital Stock |
|
123.25
+247.93%
|
35.42
+4.45%
|
33.91
+5.20%
|
32.24
|
| Common Stock |
|
123.25
+247.93%
|
35.42
+4.45%
|
33.91
+5.20%
|
32.24
|
| Share Issued |
|
7.64
+68.78%
|
4.52
+19.94%
|
3.77
+7.21%
|
3.52
|
| Ordinary Shares Number |
|
7.64
+68.78%
|
4.52
+19.94%
|
3.77
+7.21%
|
3.52
|
| Retained Earnings |
|
-46.58
-35.60%
|
-34.35
-8.88%
|
-31.55
-30.50%
|
-24.17
|
| Gains Losses Not Affecting Retained Earnings |
|
5.37
+34.12%
|
4.01
+17.87%
|
3.40
+37.09%
|
2.48
|
| Total Equity Gross Minority Interest |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Total Capitalization |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Working Capital |
|
81.97
+1401.84%
|
5.46
-16.44%
|
6.53
-37.65%
|
10.48
|
| Invested Capital |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Total Debt |
|
0.13
+5.73%
|
0.12
+61.74%
|
0.07
-47.43%
|
0.14
|
| Capital Lease Obligations |
|
0.13
+5.73%
|
0.12
+61.74%
|
0.07
-47.43%
|
0.14
|
| Net Tangible Assets |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Tangible Book Value |
|
82.04
+1381.93%
|
5.54
-16.09%
|
6.60
-37.41%
|
10.54
|
| Other Equity Interest |
|
—
|
0.46
-45.23%
|
0.83
|
—
|
| Line Item | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.69
-369.77%
|
-1.85
+73.66%
|
-7.02
+48.30%
|
-13.59
|
| Cash Flow From Continuing Operating Activities |
|
-8.69
-369.77%
|
-1.85
+73.66%
|
-7.02
+48.30%
|
-13.59
|
| Net Income From Continuing Operations |
|
-12.23
-336.46%
|
-2.80
+61.99%
|
-7.37
+50.74%
|
-14.96
|
| Depreciation Amortization Depletion |
|
0.08
+4.79%
|
0.07
+1.25%
|
0.07
+1100.10%
|
0.01
|
| Depreciation |
|
0.08
+4.79%
|
0.07
+1.25%
|
0.07
+1100.10%
|
0.01
|
| Depreciation And Amortization |
|
0.08
+4.79%
|
0.07
+1.25%
|
0.07
+1100.10%
|
0.01
|
| Other Non Cash Items |
|
0.04
+300.79%
|
0.01
-54.71%
|
0.02
-32.88%
|
0.03
|
| Stock Based Compensation |
|
3.18
+279.00%
|
0.84
-27.11%
|
1.15
+31.66%
|
0.88
|
| Asset Impairment Charge |
|
—
|
0.00
|
0.00
-100.00%
|
0.00
|
| Operating Gains Losses |
|
-0.31
-2987.96%
|
-0.01
-122.33%
|
0.05
+117.52%
|
-0.26
|
| Net Foreign Currency Exchange Gain Loss |
|
-0.31
-2987.96%
|
-0.01
-122.33%
|
0.05
+117.52%
|
-0.26
|
| Change In Working Capital |
|
0.55
+1294.00%
|
0.04
+104.23%
|
-0.94
-230.05%
|
0.72
|
| Change In Receivables |
|
-0.36
-2639.92%
|
-0.01
-111.15%
|
0.12
+360.33%
|
-0.05
|
| Change In Prepaid Assets |
|
-0.77
-308.22%
|
-0.19
-238.17%
|
0.14
+3519.30%
|
0.00
|
| Change In Payables And Accrued Expense |
|
1.69
+598.01%
|
0.24
+120.21%
|
-1.20
-256.30%
|
0.77
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
85.57
+10456.43%
|
0.81
-62.98%
|
2.19
-57.86%
|
5.20
|
| Cash Flow From Continuing Financing Activities |
|
85.57
+10456.43%
|
0.81
-62.98%
|
2.19
-57.86%
|
5.20
|
| Net Issuance Payments Of Debt |
|
-0.10
-11.61%
|
-0.09
-4.20%
|
-0.09
-1102.35%
|
-0.01
|
| Repayment Of Debt |
|
-0.10
-11.61%
|
-0.09
-4.20%
|
-0.09
-1102.35%
|
-0.01
|
| Long Term Debt Payments |
|
-0.10
-11.61%
|
-0.09
-4.20%
|
-0.09
-1102.35%
|
-0.01
|
| Net Long Term Debt Issuance |
|
-0.10
-11.61%
|
-0.09
-4.20%
|
-0.09
-1102.35%
|
-0.01
|
| Net Common Stock Issuance |
|
82.10
+9021.95%
|
0.90
-26.08%
|
1.22
-69.83%
|
4.03
|
| Proceeds From Stock Option Exercised |
|
3.93
+1301295.70%
|
0.00
-99.97%
|
1.09
-44.87%
|
1.97
|
| Net Other Financing Charges |
|
-0.36
|
—
|
-0.03
+96.63%
|
-0.80
|
| Changes In Cash |
|
76.88
+7494.66%
|
-1.04
+78.50%
|
-4.83
+42.38%
|
-8.39
|
| Effect Of Exchange Rate Changes |
|
0.31
+2567.45%
|
0.01
+125.84%
|
-0.05
-117.52%
|
0.26
|
| Beginning Cash Position |
|
5.72
-15.23%
|
6.75
-41.97%
|
11.63
-41.15%
|
19.76
|
| End Cash Position |
|
82.91
+1349.43%
|
5.72
-15.23%
|
6.75
-41.97%
|
11.63
|
| Free Cash Flow |
|
-8.69
-369.77%
|
-1.85
+73.66%
|
-7.02
+48.30%
|
-13.59
|
| Common Stock Issuance |
|
82.10
+9021.95%
|
0.90
-26.08%
|
1.22
-69.83%
|
4.03
|
| Issuance Of Capital Stock |
|
82.10
+9021.95%
|
0.90
-26.08%
|
1.22
-69.83%
|
4.03
|
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|